Equity Overview
Price & Market Data
Price: $2.89
Daily Change: +$0.02 / 0.69%
Range: $2.80 - $2.94
Market Cap: $247,167,840
Volume: 257,474
Performance Metrics
1 Week: -2.69%
1 Month: -9.12%
3 Months: -8.54%
6 Months: -18.82%
1 Year: -22.52%
YTD: -13.73%
Company Details
Employees: 56
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United States
Details
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.